Research programme: kinase inhibitors - Portola Pharmaceuticals

Drug Profile

Research programme: kinase inhibitors - Portola Pharmaceuticals

Alternative Names: Dual SYK/JAK inhibitors - Portola; JAK programme - Portola Pharmaceuticals; PRT 0318; PRT 2761; PRT060318; PRT318; Syk kinase inhibitors - Biogen/Portola

Latest Information Update: 19 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Portola Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors; Janus kinase inhibitors; Janus kinase-2 inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders; Haematological malignancies; Inflammation
  • Discontinued Thrombosis

Most Recent Events

  • 05 May 2015 Portola and Ora agree to co-develop PRT 2761 for Ophthalmic indications
  • 27 Oct 2014 Aciex Therapeutics has been acquired by NicOx
  • 16 Oct 2013 Discontinued - Preclinical for Thrombosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top